Abstracts Archive - Page 596 of 2607 - ACR Meeting Abstracts

Abstract Number: 1699 • ACR Convergence 2022
Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations
Yidan Wang¹, Miranda Gurra¹, Carla Cuda¹, Hadijat Makinde¹, Shangyang Chen¹, Gaurav Gadhvi¹, Salina Dominguez¹, Caroline Shah¹, Deborah Winter² and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Skokie, IL
Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of circulating monocytes – either classical or non-classical monocytes – is not…
Abstract Number: 1689 • ACR Convergence 2022
Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
Ramadan Ali¹, Miela Zahavi², Christine Rysenga¹, Cyrus Sarosh³, Claire Hoy¹, Kristen Demoruelle⁴ and Jason S Knight⁵, ¹University of Michigan, Ann Arbor, MI, ²Universtiy of Michigan, Ann Arbor, MI, ³University of Michigan, Temperance, MI, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: It has previously been reported that 6-gingerol, the most abundant phytochemical in ginger root, inhibits neutrophil phosphodiesterase activity and thereby counteracts neutrophil hyperactivity in…
Abstract Number: 1697 • ACR Convergence 2022
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
Anne Troldborg¹, Mads Lamm Larsen¹, Erik J.M. Toonen², Lisa Hurler³, Zoltan Prohaszka³, László Cervenak³, Annette Gudmann Hansen⁴ and Steffen Thiel⁴, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Hycult Biotech, Arnhem-Nijmegen, Netherlands, ³Semmelweis University, Budapest, Hungary, ⁴Aarhus University, Aarhus, Denmark
Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
Abstract Number: 1710 • ACR Convergence 2022
CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus
Mitra Maz¹, Hong Shi², Sonya Wolf-Fortune³, Shannon Estadt³, Alayka Reddy³, Rachael Wasikowski³, Alex Tsoi³, Celine Berthier³ and J. Michelle Kahlenberg³, ¹University of Michigan Medical School, Ann Arbor, MI, ²Department of Internal Medicine/Division of Rheumatology, Vascular Biology Center, Augusta, GA, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by overproduction of type I interferons (IFNs) and sensitivity to ultraviolet (UV) light. Though…
Abstract Number: 1704 • ACR Convergence 2022
Interaction of Macrophages and Natural Killer Cells in Pathogenesis of HIV-1-Associated Inflammatory Arthritis
Can Sungur¹, Gao Hongbo¹, Li-ping Yang², Liang Shan¹ and Wayne Yokoyama³, ¹Washington University, St. Louis, MO, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO
Background/Purpose: Human immunodeficiency virus (HIV) remains a significant life-threatening agent and burden on public health. Lesser studied and understood aspects of HIV infections include HIV-associated…
Abstract Number: 1706 • ACR Convergence 2022
Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection
Emmanuel Abimelec Camacho-Morán¹, jiram torres-Ruiz¹, Jaquelin Lira-Luna¹, Ana Sofía Vargas-Castro², Alfredo Pérez-Fragoso¹, Miroslava Nuñez-Aguirre², Beatriz Alcalá-Carmona³, Abdiel Absalón-Aguilar³ and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Post-COVID19 syndrome has been defined as the persistence of symptoms and/or organic damage for more than three weeks after the presence of clinical infection…
Abstract Number: 1702 • ACR Convergence 2022
Targeting CD6-CD318 Axis with UMCD6 (anti-CD6) Enhances in Vivo Killing of Cancer Cells Through Direct Activation of NK Cells
Mikel Gurrea-Rubio¹, Qi Wu¹, Eliza Pei-Suen Tsou¹, M. Asif Amin¹, Phillip Campbell¹, Peggy Randon¹, Matthew Lind¹, Sarah Ory¹, Camila Amarista¹, Sirapa Vichaikul², Jeffrey Ruth¹, Feng Ling³ and David Fox¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, Howell, MI, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Immune checkpoint inhibitors represent a major advance in cancer treatment, but disease prognosis continues to be poor for most patients. Resistance of cancer cells…
Abstract Number: 1713 • ACR Convergence 2022
Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus
Georgina Galicia-Rosas, María Botía Sánchez, Daniel Toro-Domínguez, Lorena Albadalejo and Marta Alarcon-Riquelme, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: Mucosa-associated commensal bacteria have been shown to be involved in the pathogenesis of systemic lupus erythematosus (SLE). However, its exact role remains to be…
Abstract Number: 1715 • ACR Convergence 2022
Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice
Xiaoqing Zheng¹, Mikhail Dozmorov², Colleen Strohlein¹, Sheldon Bastacky¹ and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Virginia Commonwealth University, Richmond, VA
Background/Purpose: Enhancer of zeste homolog 2 (EZH2) has been shown to regulate early B cell development and the differentiation of antibody secreting cells (ASCs). We…
Abstract Number: 1712 • ACR Convergence 2022
The Lymph Node Microenvironment in SLE Mice Is Altered and Impairs Egress of T Lymphocytes
Mir Howlader¹, Audrey Baeyens², Susan Schwab² and theresa Lu³, ¹Weill Cornell Medical College, Brooklyn, NY, ²New York University Grossman School of Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: T cell entry into and exit from lymph nodes (LNs) exposes T cells to antigens/cytokines required for their activation and regulates the nature of…
Abstract Number: 1714 • ACR Convergence 2022
The Circadian Clock Gene Bmal1 Negatively Regulates Autoantibody Production in SLE
Shuichiro Nakabo¹, Donavon Sandoval-Heglund¹, Victoria Hoffmann², Mingzeng Zhang¹, Norio Hanata¹, Zerai Manna¹, Elaine Poncio¹, Sarfaraz Hasni³ and Mariana Kaplan⁴, ¹NIAMS/NIH, Bethesda, MD, ²ORS/ORF/NIH, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple organs including kidney and skin. While its etiology and pathogenesis are still…
Abstract Number: 1210 • ACR Convergence 2022
Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
Namrata Singh¹, Alexander Peterson², Aaron Baraff², Ajay Gopal³, Nicholas Smith⁴, Jennifer Barton⁵, Jeffrey Curtis⁶ and Noel Weiss³, ¹University of Washington, Bellevue, WA, ²VA Puget Sound, SEATTLE, WA, ³University of Washington, Seattle, WA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) are associated with lymphoma development [1]. Whether the decrease…
Abstract Number: 1656 • ACR Convergence 2022
Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial
Anca Askanase¹, Ouali Berkani², clélia Cahuzac³, peter Cornelisse³, David D'Cruz⁴, Kenneth Kalunian⁵, Joan Merrill⁶, Marilia Pozzobon³ and Sandra Navarra⁷, ¹Columbia University Medical Center, New York, NY, ²IDORSIA, Allschwil, Switzerland, ³Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵University of California San Diego, La Jolla, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷University of Santo Tomas, Manila, Philippines
Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs. In an SLE proof-of-concept study, cenerimod—a potent, selective S1P receptor modulator—reduced lymphocyte count and disease activity…
Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
nozima Aripova¹, George Reed², Bryant England¹, William Robinson³, Dimitrios Pappas⁴, Joel Kremer⁵, Geoffrey Thiele¹ and Ted Mikuls⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²The Corrona Research Foundation and University of Massachusetts, Albany, NY, ³Stanford University School of Medicine, Palo Alto, CA, ⁴CorEvitas, LLC, Waltham, MA, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…
Abstract Number: 1463 • ACR Convergence 2022
Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria
Shudan Wang¹, Allan Spielman², Mindy Ginsberg², Michelle Petri³, Brad Rovin⁴, Jill Buyon⁵ and Anna Broder⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴The Ohio State University, Columbus, OH, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: Lupus nephritis remains a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current guidelines recommend performing a kidney biopsy at urine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].